Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130607 | 0.93 | MAPK14 (0.56) | MAPK14MAOBMETAP1CYP19A1 | |
| SCHEMBL251842 | 0.86 | MAOB (0.54) | MAPK14MAOBMETAP1CYP19A1 | |
| SCHEMBL268592 | 0.86 | KDM4E (0.56) | MAOBMETAP1CYP19A1 | |
| SCHEMBL29392039 | 0.86 | MAOB (0.54) | MAPK14MAOBMETAP1CYP19A1 | |
| SCHEMBL7491470 | 0.85 | MAPK14 (0.56) | MAPK14METAP1CYP19A1 | |
| Water SCHEMBL28454486 | 0.85 | KDM4E (0.54) | MAOBMETAP1CYP19A1 | |
| SCHEMBL15869785 | 0.83 | MPO (0.51) | METAP1CYP19A1 | |
| SCHEMBL29726014 | 0.81 | CASP1 (0.59) | MAOBMAOAMETAP1 | |
| SCHEMBL423287 | 0.81 | CASP1 (0.59) | MAOBMAOAMETAP1 | |
| SCHEMBL27632859 | 0.81 | CASP1 (0.59) | MAOBMAOAMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1435961-A4 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435962-A2 | TREATMENT OF TYPE I DIABETES | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435961-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003017926-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003017925-A2 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002067936-A1 | METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELL PATHWAYS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |